Search
Panobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … Panobinostat is marketed by Novartis under the brand name Farydak.
Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Perampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalIt is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
Activated charcoal
go.drugbank.com/drugs/DB09278ApprovedInvestigationalIt works by binding to the poison in the gastric contents in a reversible fashion thus may be adminstered together with a cathartic to reduce the small intestine transit time. … It is used as a gastric decontaminant and emergency medication to treat poisonings following excessive oral ingestion of certain medications or poisons by absorbing most drugs and toxins.
Mixtures: NO-GAS GIULIANI CARBOSYLANE, NO-GAS GIULIANI CARBOSYLANEProducts: EZ CharChlorpheniramine
go.drugbank.com/drugs/DB01114ApprovedInvestigationalA histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications.
Mixtures: Cold Relief Multi-Symptom, Daytime, Nighttime, Non-drowsy, Cold Formula Daytime Nighttime, Non-Aspirin, Multi-SymptomSynonyms: 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine, 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamineCarbocisteine
go.drugbank.com/drugs/DB04339ApprovedInvestigational[A230993] Carbocisteine is currently not FDA or Health Canada approved, but is approved for use in Asia, Europe, and South America. … Carbocisteine is a mucolytic drug that alleviates respiratory symptoms and infections by reducing the viscosity of mucus, allowing it to be expelled.
Products: MADECASOL NPhosphatidyl serine
go.drugbank.com/drugs/DB00144ApprovedNutraceuticalThis is part of the process by which the cell is targeted for phagocytosis. PS has been shown to slow cognitive decline in animal models.
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. … Higher percentages (65-78%) of the patients receiving lusutrombopag required no platelet transfusion prior to the primary invasive procedure compared to those receiving placebo [L4166].
Foreskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedOrcel, another skin substitute, is similar to Apligraf since it contains both fibroblasts and keratinocytes derived from neonatal foreskin, but in addition, utilizes a type I collagen sponge as its matrix … Apligraf has been useful in the treatment of venous leg ulcers and diabetic foot ulcers, by increasing rates of wound healing and decreasing the time required for closure of wounds [L2452].
Raxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigational[A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272] … It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions
Synonyms: RNA (recombinant 5′-[1,2-[(3′-O-methyl)m7G-(5′→5′)-ppp-Am]]-capped all uridine→N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptideBepotastine
go.drugbank.com/drugs/DB04890ApprovedBepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. … Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the